Jackie Hunter PhD DSc CBE FBPharmacolS FMedSci

Jackie Hunter PhD DSc CBE FBPharmacolS FMedSci is a prominent British scientist and pharmaceutical industry leader with an extensive background in drug discovery and development.12 She is currently the CEO of OI Pharma Partners Ltd, a consultancy she established to promote open innovation in the life sciences.1

Career Highlights

Jackie Hunter has had a distinguished career spanning academia, industry, and public service:

• Board Director at BenevolentAI, where she previously established the drug discovery arm1
• Visiting Professor at St George's Hospital Medical School and Imperial College1
• Chair of the Trustees of the Sainsbury Laboratories at Norwich1
• Chair of the Board of Stevenage Bioscience Catalyst1
• Chair of the Board of Brainomix, an AI-enabled imaging company1
• Former CEO of the Biotechnology and Biological Sciences Research Council (BBSRC)1

Prior to founding OI Pharma Partners, Dr. Hunter held senior positions in the pharmaceutical industry, including:

• Head of Neurology and GI Centre of Excellence for Drug Discovery at GlaxoSmithKline (GSK)1
• Developer of GSK's external innovation strategy1
• Various roles at SmithKline and French (later SmithKlineBeecham)1

Education and Qualifications

Dr. Hunter's educational background includes:

• PhD from London Zoo on olfaction, aggression, and sexual behavior of owl monkeys1
• BSc in Physiology and Psychology from Bedford College, University of London1

Honors and Awards

Jackie Hunter has received numerous accolades for her contributions to science and the pharmaceutical industry:

• Commander of the Order of the British Empire (CBE) for Services to the Pharmaceutical Industry (2010)1
• Fellow of the Academy of Medical Sciences (FMedSci)1
• Fellow of the British Pharmacological Society (FBPharmacolS)1
• Fellow of the Royal Society of Biology (FRSB)1
• Named one of the top 20 Women Globally Advancing AI research by Forbes Magazine (2017)1

Dr. Hunter's expertise in pharmaceutical research, drug development, and open innovation strategies has made her a respected figure in the life sciences industry.